PL3359666T3 - Wczesna izolacja komórek po transfekcji (epic) do wytwarzania środków biologicznych - Google Patents

Wczesna izolacja komórek po transfekcji (epic) do wytwarzania środków biologicznych

Info

Publication number
PL3359666T3
PL3359666T3 PL16788603.5T PL16788603T PL3359666T3 PL 3359666 T3 PL3359666 T3 PL 3359666T3 PL 16788603 T PL16788603 T PL 16788603T PL 3359666 T3 PL3359666 T3 PL 3359666T3
Authority
PL
Poland
Prior art keywords
epic
cells
early post
biologics production
transfection isolation
Prior art date
Application number
PL16788603.5T
Other languages
English (en)
Inventor
Victor R. Cairns
Christine Demaria
Jason VITKO
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL3359666T3 publication Critical patent/PL3359666T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1086Preparation or screening of expression libraries, e.g. reporter assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Optical investigation techniques, e.g. flow cytometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Optical investigation techniques, e.g. flow cytometry
    • G01N15/149Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70592CD52

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL16788603.5T 2015-10-09 2016-10-07 Wczesna izolacja komórek po transfekcji (epic) do wytwarzania środków biologicznych PL3359666T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562239515P 2015-10-09 2015-10-09
PCT/US2016/055918 WO2017062724A1 (en) 2015-10-09 2016-10-07 Early post-transfection isolation of cells (epic) for biologics production

Publications (1)

Publication Number Publication Date
PL3359666T3 true PL3359666T3 (pl) 2025-06-23

Family

ID=57211576

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16788603.5T PL3359666T3 (pl) 2015-10-09 2016-10-07 Wczesna izolacja komórek po transfekcji (epic) do wytwarzania środków biologicznych
PL16788602.7T PL3359665T3 (pl) 2015-10-09 2016-10-07 Ulepszona technologia flare (atenuowana ekspresja reportera z zastosowaniem cytometrii przepływowej) do sortowania z szybkim grupowaniem

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16788602.7T PL3359665T3 (pl) 2015-10-09 2016-10-07 Ulepszona technologia flare (atenuowana ekspresja reportera z zastosowaniem cytometrii przepływowej) do sortowania z szybkim grupowaniem

Country Status (12)

Country Link
US (4) US10317329B2 (pl)
EP (4) EP3359666B1 (pl)
CN (3) CN116660127A (pl)
AU (3) AU2016335699A1 (pl)
CA (2) CA3001238C (pl)
ES (2) ES3024209T3 (pl)
HU (2) HUE071193T2 (pl)
IL (4) IL309289A (pl)
MX (1) MX2018004366A (pl)
PL (2) PL3359666T3 (pl)
SG (3) SG11201802829YA (pl)
WO (2) WO2017062722A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
EP3359666B1 (en) 2015-10-09 2025-02-19 Genzyme Corporation Early post-transfection isolation of cells (epic) for biologics production
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
BR112018073472A2 (pt) 2016-05-18 2019-08-27 Voyager Therapeutics, Inc. composições e métodos de tratamento da doença de huntington
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
CL2016001661A1 (es) * 2016-06-29 2017-03-03 Univ Chile Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes.
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
MX2019004013A (es) 2016-10-07 2019-08-14 Genzyme Corp Aislamiento temprano de celulas despues de la transfeccion (epic) para la produccion de productos biologicos.
CN111108198A (zh) 2017-05-05 2020-05-05 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
AU2019268330A1 (en) 2018-05-15 2020-11-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CN116615655A (zh) 2020-11-19 2023-08-18 建新公司 流式细胞术减弱报告物表达(flare)多种报告物系统及其使用方法
US20250281605A1 (en) 2024-03-08 2025-09-11 Sanofi Antigenic Epstein Barr Virus Polypeptides

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
CA2063799A1 (en) 1989-07-24 1991-01-25 Frank S. Genbauffe Prevention of internal initiation
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
WO1998037189A1 (en) 1997-02-25 1998-08-27 Qbi Enterprises Ltd. Ires sequences with high translational efficiency and expression vectors containing the sequence
US7001733B1 (en) * 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US20050005310A1 (en) * 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
CA2385102A1 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Expression vectors and methods
US20020058243A1 (en) 2000-02-02 2002-05-16 Kurt Jarnigan Rapid, parallel identification of cell lines
US6833254B2 (en) 2001-03-01 2004-12-21 The Regents Of The University Of California Method to identify IRES elements
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
DE10143238A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente
US20050221325A1 (en) 2002-05-22 2005-10-06 Greg Thill Detection of secreted polypeptides
US7119187B2 (en) 2002-07-09 2006-10-10 National Health Research Institutes Internal ribosome entry site of the labial gene for protein expression
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EP1540008A4 (en) * 2002-07-19 2006-04-12 Diversa Corp FLUORESCENT PROTEINS, NUCLEIC ACIDS ENCODING THEM, AND METHODS OF MAKING AND USING SAME
US7344886B2 (en) 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US20060173168A1 (en) 2002-12-16 2006-08-03 Wayne State University Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20
EP3346010A1 (en) 2003-06-24 2018-07-11 Genzyme Corporation Novel beta-actin and rps21 promoters and uses thereof
US7776584B2 (en) 2003-08-01 2010-08-17 Genetix Limited Animal cell colony picking apparatus and method
EP1749538A4 (en) 2004-03-31 2009-11-11 Kirin Pharma Kk METHOD FOR DETERMINING THE DIFFERENTIATION OF REGULATORY T CELLS AND THEIR PROLIFERATION WITH GPI ANCHOR PROTEIN AGONISTS AND MEDICINAL COMPOSITION THEREFOR
US7078179B2 (en) 2004-05-04 2006-07-18 Newlink Genetics Corporation Selectable gene marker system based on expression of N-acetyllactosaminide 3-α galactosyltransferase
WO2006023248A2 (en) * 2004-07-28 2006-03-02 The Trustees Of Columbia University In The City Of New York Processes for producing and crystallizing g-protein coupled receptors
AU2005300503B2 (en) 2004-11-08 2010-12-16 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20060172382A1 (en) 2004-11-08 2006-08-03 Chromagenics B.V. Selection of host cells expressing protein at high levels
CN101068928A (zh) * 2004-12-14 2007-11-07 弗·哈夫曼-拉罗切有限公司 RNAi转染子的改良选择方法
KR101087809B1 (ko) 2006-04-10 2011-11-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 단일 세포 및 콜로니의 수집을 위한 시스템
EP2064337B1 (en) 2006-09-20 2012-07-18 Genzyme Corporation A facs-and reporter protein-based system for high throughput development of therapeutic proteins
CA2679393A1 (en) * 2007-03-05 2008-09-12 Newsouth Innovations Pty Limited Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents
JP6039552B2 (ja) * 2010-07-01 2016-12-07 グラクソ グループ リミテッドGlaxo Group Limited 高産生細胞株を選択するための改良された方法
EP2834259A4 (en) * 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
EP2700713B1 (en) * 2012-08-21 2016-07-13 Miltenyi Biotec GmbH Screening and enrichment system for protein expression in eukaryotic cells using a tricistronic expression cassette
US20160017319A1 (en) * 2013-03-11 2016-01-21 Audrey Nommay Method of screening cell clones
RU2716977C2 (ru) * 2013-07-31 2020-03-17 Новартис Аг Новые селективные векторы и способы селекции эукариотических клеток-хозяев
EP3359666B1 (en) 2015-10-09 2025-02-19 Genzyme Corporation Early post-transfection isolation of cells (epic) for biologics production
MX2019004013A (es) 2016-10-07 2019-08-14 Genzyme Corp Aislamiento temprano de celulas despues de la transfeccion (epic) para la produccion de productos biologicos.

Also Published As

Publication number Publication date
IL297805A (en) 2022-12-01
SG11201802823VA (en) 2018-05-30
IL258538A (en) 2018-05-31
AU2025226783A1 (en) 2025-09-25
EP3359666C0 (en) 2025-02-19
EP3359666B1 (en) 2025-02-19
IL258538B2 (en) 2023-04-01
AU2022275507A1 (en) 2023-02-02
EP4567425A2 (en) 2025-06-11
CN108368504A (zh) 2018-08-03
IL258537A (en) 2018-05-31
SG11201802829YA (en) 2018-05-30
HK1259493A1 (en) 2019-11-29
IL258537B2 (en) 2024-05-01
PL3359665T3 (pl) 2025-04-14
WO2017062722A2 (en) 2017-04-13
CA3001364A1 (en) 2017-04-13
IL258537B1 (en) 2024-01-01
US10317329B2 (en) 2019-06-11
EP4567425A3 (en) 2025-10-08
EP4530350A2 (en) 2025-04-02
US20170227441A1 (en) 2017-08-10
WO2017062724A1 (en) 2017-04-13
CA3001238C (en) 2024-06-25
US11635363B2 (en) 2023-04-25
EP4530350A3 (en) 2025-06-25
SG10202111233SA (en) 2021-11-29
CN116660127A (zh) 2023-08-29
US20230304913A1 (en) 2023-09-28
ES3024209T3 (en) 2025-06-04
EP3359666A1 (en) 2018-08-15
US20200018682A1 (en) 2020-01-16
HUE069884T2 (hu) 2025-04-28
EP3359665B1 (en) 2024-11-13
EP3359665C0 (en) 2024-11-13
MX2018004366A (es) 2018-08-01
CA3001238A1 (en) 2017-04-13
WO2017062722A3 (en) 2017-05-26
CN108368504B (zh) 2022-07-19
IL258538B (en) 2022-12-01
EP3359665A2 (en) 2018-08-15
ES3008383T3 (en) 2025-03-24
HUE071193T2 (hu) 2025-08-28
AU2022275507B2 (en) 2025-06-05
CN108368505B (zh) 2023-02-21
CN108368505A (zh) 2018-08-03
IL309289A (en) 2024-02-01
US20170121734A1 (en) 2017-05-04
AU2016335699A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
IL258538A (en) Early isolation after the infection of cells (epic) for the production of biological material
EP3345990A4 (en) SYSTEM FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
EP3177904A4 (en) Platelet-targeted microfluidic isolation of cells
SG11201706636PA (en) Single-cell nucleic acids for high-throughput studies
LT3365107T (lt) Ląstelių kultūra
PL3119575T3 (pl) Sposób wytwarzania izolacyjnego środnika
EP3140425A4 (en) Methods of linearly amplifying whole genome of a single cell
ZA201707477B (en) Methods for assesing the purity of a mesenchymal stem cells preparation
PL3140392T3 (pl) Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków
GB2525950B (en) Process for the production of dialkyl succinate
GB2525949B (en) Process for the production of dialkyl succinate
IL261999A (en) Cell culture process
GB201420428D0 (en) Methods for nucleic acid isolation
EP3233814A4 (en) Novel process for the preparation of ranolazine
EP3196304A4 (en) Method for improved high secretory production of proteins
PT3362405T (pt) Processo e unidade de produção para a produção de metanol
GB201504459D0 (en) Isolation of DNA
IL257814B (en) A method for preparing praziquantel
SG10202103545PA (en) Early post-transfection isolation of cells (epic) for biologics production
SG11201705939RA (en) A contractile cellular construct for cell culture
SG11201705095VA (en) Process for the manufacture of solar cells
GB201408753D0 (en) Isolation of adipose derived cells
HK40128447A (zh) 使用哺乳动物细胞产生异多聚体蛋白
SG11201609269TA (en) Method of culturing cells
EP3378945A4 (en) Method for distinguishing particular cells from mixture of heterogeneous cells